Last updated on March 2018

Shortened Aggrastat Versus Integrilin in Percutaneous Coronary Intervention


Brief description of study

The purpose this study is to assess whether a tirofiban regimen of a high-dose bolus plus a shortened infusion duration compared to label-dosing eptifibatide in patients undergoing percutaneous coronary intervention (PCI) is associated with a non-inferior composite rate of death, PCI-related myocardial infarction, urgent target vessel revascularization or in-hospital major bleeding within 48 hours following PCI or hospital discharge, whichever comes first.

Clinical Study Identifier: NCT01522417

Contact Investigators or Research Sites near you

Start Over

Debbie Douglas, PhD

Northside Hospital
Saint Petersburg, FL United States
3.78miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.